What This Site Is — and What It Is Not

The publisher

Telehealth Retatrutide is a running watch on the peer-reviewed and clinical-trial research about retatrutide (LY3437943) — a reading of the evidence, kept current as the program develops. A watch reports what it sees; it does not act. There is no clinic here, no clinician on staff, and no medical advice, and nothing is diagnosed, prescribed, or treated. Nothing is manufactured, sold, or distributed either — no telehealth consultations, no prescriptions filled, no products, and no patient-provider relationship of any kind.

The domain is an exact-match name — a publishing convention tied to the terms people search when looking for information about this compound. 'Telehealth' in it is framing, not a description of services. What the watch publishes is a reading of published science, with every claim carried back to its source.

What we track

The watch is trained on the cardiometabolic thread in retatrutide's development: weight, glycemia, liver fat, blood pressure, lipids, and the ongoing cardiovascular and kidney outcome trials. That lens was chosen because the Phase 2 findings in those domains are among the most clinically significant in the incretin-class literature to date — and because the Phase 3 program will ultimately answer whether those metabolic signals translate to reduced cardiovascular and kidney events.

Published findings from Phase 1b through Phase 3, structural biology, meta-analyses, and the most recent 2024-2026 studies are summarized here. Every quantitative claim is cited to a numbered reference; where the evidence is uncertain or incomplete, that is said. The watch follows the evidence as it moves from Phase 2 toward potential regulatory review — measured optimism grounded in what the data actually show.

What we are not

There is no affiliation with Eli Lilly or any pharmaceutical company, no financial relationship with any vendor, clinical trial, compound supplier, or healthcare provider, and no funding from any party with a commercial interest in retatrutide.

There are no doctors, pharmacists, or clinical staff. Whether to use retatrutide is not advised on. No sourcing guidance is given and no suppliers are linked. Any language describing reported effects or community signals is commentary on what people have reported in public forums — not a recommendation, endorsement, or clinical finding.

Retatrutide is investigational. Nothing here should be read as an instruction, a suggestion, or a basis for a personal decision about your own health. Those decisions belong to you and, where relevant, a licensed healthcare provider who knows your individual situation.

Contact and corrections

Accuracy is taken seriously. A citation error, a factual misstatement, or a claim that appears to exceed what the cited study found — please use the contact page to flag it, and it will be reviewed and corrected promptly. The Retatrutide references page lists every source used; all are publicly accessible.